HDAC9 and hematopoietic and lymphoid cell neoplasm: The pan-HDAC inhibitors vorinostat, panobinostat and belinostat, and the class I-specific HDAC inhibitor romidepsin have been approved by the US Food and Drug Administration for the treatment of hematological cancers.